Crossmark

Double-blinded, randomized tolerance study of a biologically enhanced Nanogel with endothelin-1 and bradykinin receptor antagonist peptides via intra-articular injection for osteoarthritis treatment in horses

Crossref DOI link: https://doi.org/10.1186/s12917-024-04352-w

Published Online: 2024-12-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Terlinden, Antoinette

Jacquet, Sandrine

Manivong, Seng

Cullier, Aurélie

Cassé, Frédéric

Legendre, Florence

Garcia, Araceli Ac

Roullin, Gaëlle

Moldovan, Florina

Sirois, Pierre

Banquy, Xavier

Galéra, Philippe

Audigié, Fabrice

Demoor, Magali

Bertoni, Lélia
Funding

Funding for this research was provided by:

European Regional Development Fund

Arthritis Society

Institut TransMedTech

Région Normandie
License Information

Text and Data Mining valid from 2024-12-04

Version of Record valid from 2024-12-04
More Information

Article History

Received: 29 March 2024

Accepted: 23 October 2024

First Online: 4 December 2024

Declarations

:

: The study protocol was approved by the ComEth Anses/ENVA/UPEC (protocol code 21–037#30112 OA-ACTIVE).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below